Literature DB >> 1731332

Possible influences on the expression of X chromosome-linked dystrophin abnormalities by heterozygosity for autosomal recessive Fukuyama congenital muscular dystrophy.

A H Beggs1, P E Neumann, K Arahata, E Arikawa, I Nonaka, M S Anderson, L M Kunkel.   

Abstract

Abnormalities of dystrophin, a cytoskeletal protein of muscle and nerve, are generally considered specific for Duchenne and Becker muscular dystrophy. However, several patients have recently been identified with dystrophin deficiency who, before dystrophin testing, were considered to have Fukuyama congenital muscular dystrophy (FCMD) on the basis of clinical findings. Epidemiologic data suggest that only 1/3500 males with autosomal recessive FCMD should have abnormal dystrophin. To explain the observation of 3/23 FCMD males with abnormal dystrophin, we propose that dystrophin and the FCMD gene product interact and that the earlier onset and greater severity of these patients' phenotype (relative to Duchenne muscular dystrophy) are due to their being heterozygous for the FCMD mutation in addition to being hemizygous for Duchenne muscular dystrophy, a genotype that is predicted to occur in 1/175,000 Japanese males. This model may help explain the genetic basis for some of the clinical and pathological variability seen among patients with FCMD, and it has potential implications for understanding the inheritance of other autosomal recessive disorders in general. For example, sex ratios for rare autosomal recessive disorders caused by mutations in proteins that interact with X chromosome-linked gene products may display predictable deviation from 1:1.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731332      PMCID: PMC48291          DOI: 10.1073/pnas.89.2.623

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Heredofamilial juvenile muscular atrophy simulating muscular dystrophy.

Authors:  E KUGELBERG; L WELANDER
Journal:  AMA Arch Neurol Psychiatry       Date:  1956-05

2.  Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications.

Authors:  J T Den Dunnen; P M Grootscholten; E Bakker; L A Blonden; H B Ginjaar; M C Wapenaar; H M van Paassen; C van Broeckhoven; P L Pearson; G J van Ommen
Journal:  Am J Hum Genet       Date:  1989-12       Impact factor: 11.025

3.  Thalassaemia intermedia: interaction of the triple alpha-globin gene arrangement and heterozygous beta-thalassaemia.

Authors:  A E Kulozik; S L Thein; J S Wainscoat; R Gale; L A Kay; J K Wood; D J Weatherall; E R Huehns
Journal:  Br J Haematol       Date:  1987-05       Impact factor: 6.998

4.  Dystrophin diagnosis: comparison of dystrophin abnormalities by immunofluorescence and immunoblot analyses.

Authors:  K Arahata; E P Hoffman; L M Kunkel; S Ishiura; T Tsukahara; T Ishihara; N Sunohara; I Nonaka; E Ozawa; H Sugita
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction.

Authors:  A H Beggs; M Koenig; F M Boyce; L M Kunkel
Journal:  Hum Genet       Date:  1990-11       Impact factor: 4.132

6.  Localization of dystrophin to postsynaptic regions of central nervous system cortical neurons.

Authors:  H G Lidov; T J Byers; S C Watkins; L M Kunkel
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

7.  Immunocytochemical analysis of dystrophin in congenital muscular dystrophy.

Authors:  E Arikawa; T Ishihara; I Nonaka; H Sugita; K Arahata
Journal:  J Neurol Sci       Date:  1991-09       Impact factor: 3.181

8.  Membrane organization of the dystrophin-glycoprotein complex.

Authors:  J M Ervasti; K P Campbell
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

9.  The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.

Authors:  M Koenig; A H Beggs; M Moyer; S Scherpf; K Heindrich; T Bettecken; G Meng; C R Müller; M Lindlöf; H Kaariainen; A de la Chapellet; A Kiuru; M L Savontaus; H Gilgenkrantz; D Récan; J Chelly; J C Kaplan; A E Covone; N Archidiacono; G Romeo; S Liechti-Gailati; V Schneider; S Braga; H Moser; B T Darras; P Murphy; U Francke; J D Chen; G Morgan; M Denton; C R Greenberg; K Wrogemann; L A Blonden; M B van Paassen; G J van Ommen; L M Kunkel
Journal:  Am J Hum Genet       Date:  1989-10       Impact factor: 11.025

Review 10.  Population frequencies of inherited neuromuscular diseases--a world survey.

Authors:  A E Emery
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

View more
  7 in total

Review 1.  The molecular basis of genetic dominance.

Authors:  A O Wilkie
Journal:  J Med Genet       Date:  1994-02       Impact factor: 6.318

2.  From genotype to phenotype: genetics and medical practice in the new millennium.

Authors:  D Weatherall
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-12-29       Impact factor: 6.237

3.  Duchenne Muscular Dystrophy and Early Onset Hypertrophic Cardiomyopathy associated with Mutations in Dystrophin and Hypertrophic Cardiomyopathy-Associated Genes.

Authors:  Liam Aspit; Noga Arwas; Hanna Krymko; Yoram Etzion; Ruti Parvari; Aviva Levitas
Journal:  J Pediatr Genet       Date:  2020-11-19

4.  Intestinal pseudo-obstruction in myotonic dystrophy.

Authors:  H G Brunner; B C Hamel; P Rieu; C J Höweler; F T Peters
Journal:  J Med Genet       Date:  1992-11       Impact factor: 6.318

5.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

6.  X-chromosome methylation in manifesting and healthy carriers of dystrophinopathies: concordance of activation ratios among first degree female relatives and skewed inactivation as cause of the affected phenotypes.

Authors:  J Azofeifa; T Voit; C Hübner; M Cremer
Journal:  Hum Genet       Date:  1995-08       Impact factor: 4.132

7.  Severe dystrophinopathy in a patient with congenital hypotonia.

Authors:  G Cordone; M Bado; G Morreale; M Pedemonte; C Minetti
Journal:  Childs Nerv Syst       Date:  1996-08       Impact factor: 1.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.